ATE468119T1 - Verfahren zur behandlung von krebs - Google Patents

Verfahren zur behandlung von krebs

Info

Publication number
ATE468119T1
ATE468119T1 AT07736446T AT07736446T ATE468119T1 AT E468119 T1 ATE468119 T1 AT E468119T1 AT 07736446 T AT07736446 T AT 07736446T AT 07736446 T AT07736446 T AT 07736446T AT E468119 T1 ATE468119 T1 AT E468119T1
Authority
AT
Austria
Prior art keywords
treating cancer
mammal
cancer
treating
oleandomycin
Prior art date
Application number
AT07736446T
Other languages
German (de)
English (en)
Inventor
Rina Rosin-Arbesfeld
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE468119T1 publication Critical patent/ATE468119T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT07736446T 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs ATE468119T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81260506P 2006-06-12 2006-06-12
PCT/IL2007/000706 WO2007144876A1 (en) 2006-06-12 2007-06-12 Methods for treating cancer

Publications (1)

Publication Number Publication Date
ATE468119T1 true ATE468119T1 (de) 2010-06-15

Family

ID=38541966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07736446T ATE468119T1 (de) 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs

Country Status (7)

Country Link
US (1) US9486467B2 (https=)
EP (1) EP2029147B1 (https=)
JP (1) JP2009539970A (https=)
CN (1) CN101568343A (https=)
AT (1) ATE468119T1 (https=)
DE (1) DE602007006663D1 (https=)
WO (1) WO2007144876A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150098675A (ko) 2012-12-24 2015-08-28 라모트 앳 텔-아비브 유니버시티 리미티드 넌센스 돌연변이로부터 생긴 유전적 질환을 치료하기 위한 물질 및 이를 확인하는 방법
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
WO2018153954A1 (en) * 2017-02-22 2018-08-30 Immune System Regulation Holding Ab Novel immune stimulating macrolide
US11077126B2 (en) 2017-04-06 2021-08-03 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor
KR102375444B1 (ko) * 2017-07-04 2022-03-17 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 종양을 치료 및/또는 예방하는 약물 제조에서 이소발레릴 스피라마이신i, ii 및/또는 iii의 응용 및 약물
WO2019141256A1 (zh) 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 可利霉素或其活性成分的用途
CA3088818A1 (en) * 2018-01-19 2019-07-25 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Mtor inhibitor, pharmaceutical composition and use thereof
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
WO2023114231A1 (en) * 2021-12-14 2023-06-22 The Regents Of The University Of California Clustered mutations for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092473A (en) 1975-08-01 1978-05-30 Sanraku Ocean Co., Ltd. Tylosin derivatives and their manufacturing process
GB1540397A (en) 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
US4064143A (en) 1976-12-10 1977-12-20 Pfizer Inc. Oleandomycin derivatives
US4205163A (en) 1977-11-08 1980-05-27 Sanraku-Ocean Co., Ltd. Tylosin derivatives
US4124755A (en) 1978-01-03 1978-11-07 Pfizer Inc. 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
SE445739B (sv) 1978-09-14 1986-07-14 Toyo Jozo Kk 3", 4"-diacyltylosinderivat
US4429116A (en) 1982-12-27 1984-01-31 Pfizer Inc. Alkylated oleandomycin containing compounds
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
TR199900684T2 (xx) * 1996-07-08 1999-07-21 Galderma Research & Development, S.N.C. Apoptoz uyar�c� adamantil t�revleri ve bunlar�n kansere kar�� maddeler olarak kullan�m�.
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
HRP980646B1 (en) 1998-12-30 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Novel oleandomycin derivatives
IL133077A0 (en) 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
HUP0201516A3 (en) 1999-05-24 2003-03-28 Pfizer Prod Inc 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20050171032A1 (en) 2002-04-11 2005-08-04 Children's Medical Center Corporation Methods for the treatment of cancer
CN1562066A (zh) 2004-04-14 2005-01-12 山东鲁抗舍里乐药业有限公司 酒石酸泰乐菌素颗粒剂及其制备方法
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products

Also Published As

Publication number Publication date
JP2009539970A (ja) 2009-11-19
DE602007006663D1 (de) 2010-07-01
WO2007144876A1 (en) 2007-12-21
US9486467B2 (en) 2016-11-08
CN101568343A (zh) 2009-10-28
US20110306571A1 (en) 2011-12-15
EP2029147B1 (en) 2010-05-19
EP2029147A1 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
ATE468119T1 (de) Verfahren zur behandlung von krebs
NO20200775A1 (no) Fremgangsmåter og sammensetninger for behandling av kreft
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
IL240405A (en) Pharmaceuticals containing 1-pd antagonist to treat infections and tumors
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
BRPI0715845A2 (pt) Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
EP2132240A4 (en) COMPOSITIONS AND METHOD FOR TREATING A WATER BLOCKED DRILL OXIDE
EP2140103A4 (en) COMPOSITIONS AND METHOD FOR TREATING A WATER BLOCKED BOREOLE
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
CR10667A (es) Compositions and methods for diagnosing and treating cancer
AR071808A1 (es) Formulaciones orales de analogos de citidina, metodo de tratamiento, composicion farmaceutica y uso
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
PL374191A1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
UA94129C2 (ru) Соединения для ингибирования митоза
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
MY149028A (en) Nalmefene hydrochloride dihydrate
WO2007149782A3 (en) Selective inhibitors for transferases
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
EP2056840A4 (en) COMPOSITIONS, DEVICES AND METHODS OF TREATING MORBUS HUNTINGTON BY INTRA-CRANICAL LEVY FROM SIRNA
CL2008001740A1 (es) Compuestos derivados de piperidinas sustituidas, inhibidores de la dna-girasa y/o topoisomerasa iv; procedimeinto para su preparacion; composiicon farmaceutica que comprende estos compustos y su uso en el tratamiento de una infeccion bacteriana.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BRPI0913583A2 (pt) composto, composição farmacêutica, método para inibir dna girase bacteriana e/ou topoisomerase iv bacteriana, para produzir um efeito antibacteriano, e para tratar uma infecção bacteriana em um animal de sangue quente, e, uso de um composto
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties